Winners and Losers in Biopharma’s Q1 2024 Earnings Season 5/15/2024

Sands Capital Launches $555M Life Sciences Fund Focusing on Private Companies 5/15/2024

As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters 5/15/2024

FDA Delays Review by Three Months for Ascendis’ Hypoparathyroidism Therapy 5/15/2024

The Many Ways Biopharma Can Use Artificial Intelligence, Including Generative AI 5/15/2024

Bayer Layoffs, a Big Alzheimer’s Deal, and ASGCT Wrap 5/15/2024

Bayer Cuts 1,500 Jobs and Lowers 2024 Earnings Guidance as Q1 Sales Dip 5/14/2024

Novo Nordisk’s Wegovy Sustains Weight Loss for Four Years in Two Studies 5/14/2024

Cytokinetics’ Phase III Data Sets Up Cardiomyopathy Challenge to BMS 5/14/2024

AbbVie, Gilgamesh Sign Potential $2B Deal to Develop Next-Gen Psychedelics for Psychiatric Disorders 5/14/2024

Sanofi, Pfizer, AstraZeneca Pledge Nearly $2.16B in Total Investments in France 5/13/2024

Merck Ends Phase III Anti-TIGIT, Keytruda Skin Cancer Study with High Dropouts 5/13/2024

Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy 5/13/2024

BIOSECURE Act Gets Update, Gives US Drugmakers Until 2032 to Sever Ties with Chinese Biotechs 5/13/2024

Could Cancer Vaccines Be the Next Big Breakthrough in Immunotherapy? 5/13/2024

Opinion: Travere’s Filspari Could Lead IgA Nephropathy Market 5/13/2024

FDA Action Alert: Dynavax, Ascendis and BMS 5/13/2024

Excision’s CRISPR-Based HIV Treatment Fails to Show Curative Potential in Early Study 5/13/2024

Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials 5/13/2024

Lilly’s Tirzepatide Shows Positive Phase II NASH Data, Tees Up Potential Expa... 6/5/2024